Item | Diff. of VAS (PostOP3M-PostOP24M) | Diff. of BI (PostOP24M-PostOP3M) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Crude | Adjusted | Crude | Adjusted | ||||||||
β (95% CI) | p-value | β (95% CI) | p-value | β (95% CI) | p-value | β (95% CI) | p-value | ||||
Age | 0.00 (-0.03, 0.03) | 0.868 | 0.01 (-0.02, 0.04) | 0.614 | -0.10 (-0.30, 0.09) | 0.284 | -0.07 (-0.26, 0.12) | 0.447 | |||
Sex (Male vs. Female) | -1.04 (-1.81, -0.27) | 0.009* | -1.11 (-2.01, -0.20) | 0.018* | -2.14 (-2.32, -0.74) | 0.021* | -1.66 (-2.14, -0.60) | 0.016* | |||
BMI | 0.00 (-0.08, 0.08) | 0.930 | -0.05 (-0.13, 0.04) | 0.272 | -0.07 (-0.55, 0.40) | 0.764 | 0.38 (-0.18, 0.93) | 0.181 | |||
Medication (Forteo vs. Prolia) | 4.76 (-0.30, 9.82) | 0.002* | 2.07 (1.50, 4.65) | 0.002* | 3.91 (0.90, 8.71) | 0.009* | 6.80 (1.04, 12.56) | 0.021* | |||
FRAX major | 0.01 (-0.01, 0.04) | 0.331 | 0.07 (-0.10, 0.24) | 0.407 | |||||||
FRAX hip | 0.01 (-0.02, 0.04) | 0.600 | 0.10 (-0.09, 0.30) | 0.302 | |||||||
Previous medicine | - | - | - | - | - | - | |||||
None | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | |||||
Prolia | 0.61 (-0.23, 1.45) | 0.154 | -0.11 (1.70, 2.49) | 0.720 | 0.95 (-0.37, 1.27) | 0.067 | |||||
Bisphosphonate | -0.02 (-0.88, 0.85) | 0.969 | 1.38 (-3.82, 6.57) | 0.598 | -0.15 (-5.65, 5.35) | 0.956 | |||||
Dyslipidemia vs. None | -0.57 (-1.45, 0.31) | 0.200 | -1.53 (-6.91, 3.84) | 0.570 | |||||||
HTN vs. None | 0.31 (-0.32, 0.94) | 0.327 | 0.36 (-3.45, 4.16) | 0.852 | |||||||
DM vs. None | 0.26 (-0.52, 1.04) | 0.501 | -2.52 (-7.20, 2.16) | 0.286 | |||||||
CKD vs. None | -0.63 (-1.46, 0.20) | 0.136 | 3.06 (-2.01, 8.12) | 0.232 | |||||||
CAD vs. None | -0.98 (-1.89, -0.07) | 0.035* | -0.79 (-1.80, 0.22) | 0.123 | -2.41 (-8.09, 3.26) | 0.399 |